The rapid advancements in liquid biopsy technology and evolution of clinical NGS sequencing in oncology, particularly in New Zealand, allow for the non-invasive detection and monitoring of cancer through the analysis of circulating tumor DNA (ctDNA), Circulating Tumor Cells (CTCs) and other biomarkers found in bodily fluids such as blood. This method has revolutionized cancer diagnostics by offering an alternative to traditional tissue biopsies, which can be invasive and challenging in some cases. As the incidence of cancer continues to rise in New Zealand, suggesting that new cases will almost double, the demand for innovative diagnostic technologies like liquid biopsy grows. These technologies enable earlier detection, better monitoring of treatment responses, and more personalized treatment plans, thus improving patient outcomes. With an increasing shift toward precision oncology, where treatments are tailored based on the genetic makeup of individual tumors, the role of liquid biopsy becomes even more crucial. The integration of Next-Generation Sequencing (NGS) further enhances the capabilities of liquid biopsy, allowing for more comprehensive and accurate genomic profiling. As liquid biopsy technologies continue to advance, they provide more significant insights into cancer biology, offering the potential for earlier interventions, reduced treatment costs, and improved survival rates for patients in New Zealand.
Access Full Report @ https://www.databridgemarketresearch.com/reports/new-zealand-clinical-oncology-next-generation-sequencing-market
Data Bridge Market Research analyzes that the New Zealand Clinical Oncology Next Generation Sequencing Market size was valued at USD 4.12 million in 2024 and is projected to reach USD 14.83 million by 2032, with a CAGR of 17.4% during the forecast period of 2025 to 2032.
Key Findings of the Study
Increasing Incidence Rate of Cancer
The increasing incidence rate of cancer in New Zealand is a powerful driver for the expansion of clinical Next-Generation Sequencing (NGS) applications in oncology. This surge is largely attributed to the aging population, lifestyle changes, and increased environmental risk factors, which collectively contribute to the growing cancer burden. As the need for more precise, early-stage detection methods becomes ever more pressing, NGS technology stands out as a critical tool in the fight against cancer. NGS allows for the detailed genomic profiling of tumors, enabling clinicians to understand the genetic mutations driving cancer and identify targeted therapies that are most likely to be effective for individual patients. Moreover, this technology can be used for minimal-invasive liquid biopsies, reducing the need for traditional, more invasive tissue biopsies and providing a faster, more comprehensive means of tracking the disease. With the incidence of cancer expected to rise substantially, the demand for these advanced diagnostic and therapeutic technologies is set to grow, as they offer the potential to significantly improve cancer outcomes, optimize treatment plans, and reduce healthcare costs. As the healthcare system faces mounting pressure from the increasing cancer burden, the adoption of NGS in oncology represents a pivotal shift toward more personalized, precise, and effective cancer care in New Zealand.
Therefore, the demand for more sophisticated diagnostic tools intensifies in response to the higher cancer burden, and the role of NGS in transforming cancer care becomes increasingly pivotal. With NGS, oncologists can make more informed decisions, leading to better treatment plans and monitoring of disease progression. The growing recognition of the effectiveness of these technologies, paired with the rising cancer incidence, underscores the need for continued advancements and integration of NGS in clinical practice, ultimately fostering an environment where personalized cancer care becomes more accessible and impactful across New Zealand.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2025 to 2032
|
|
Base Year
|
2024
|
|
Historic Years
|
2018 to 2023 (Customizable 2013-2017)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Technology (Targeted Sequencing, Whole Exome Sequencing, and Whole Genome Sequencing), Products & Services (Consumables, Instruments, and Services), Sequencing Type (Paired End Sequencing, Single Read Sequencing), Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Lymphoma, and Others), End User (Hospitals, Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROS), and Others), Distribution Channel (Direct Tender, Retail Sales, and Others)
|
|
Countries Covered
|
New Zealand
|
|
Market Players Covered
|
Illumina Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN (Netherlands), PacBio (U.S.), Agilent Technologies, Inc. (U.S.), Zymo Research Corporation (U.S.), SOPHiA GENETICS (Switzerland), Takara Bio Inc., (Japan) and Myriad Genetics, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Devyser (Sweden), Macrogen Oceania (Australia), Mérieux NutriSciences Corporation (France), and Creative Biolabs (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
New Zealand clinical oncology next generation sequencing market is segmented into six notable segments which are based on technology, products & services, sequencing type, cancer type, end user, and distribution channel.
- On the basis of technology, the market is segmented into targeted sequencing, whole exome sequencing, and whole genome sequencing
In 2025, the targeted sequencing segment is expected to dominate the clinical oncology next generation sequencing market
In 2025, the targeted sequencing segment is expected to dominate the market with a market share of 56.17% due to its ability to focus on specific cancer-related genes, offering higher accuracy, cost-efficiency, and faster turnaround times for precision oncology applications.
- On the basis of products and services, the market is segmented into consumables, instruments, and services.
In 2025, the consumables segment is expected to dominate the clinical oncology next generation sequencing market
In 2025, the consumables segment is expected to dominate the market with a market share of 55.25% due to the ongoing need for reagents, kits, and other essential materials required for continuous NGS testing and research in cancer diagnostics and treatment.
- On the basis of sequencing type, the market is segmented into paired end sequencing and single read sequencing. In 2025, the paired end sequencing segment is expected to dominate the market with a market share of 66.91%
- On the basis of cancer type, the market is segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, lymphoma, and others. In 2025, the lung cancer segment is expected to dominate the market with a market share of 24.08%
- On the basis of end user, the market is segmented into hospitals, clinical laboratories, academic & research institutes, pharmaceutical & biotechnology companies, Contract Research Organizations (CROS), and others. In 2025, the hospitals segment is expected to dominate the market with a market share of 49.15%
- On the basis of distribution channel, the market is segmented into direct tender, retail sales, and others. In 2025, the direct tender segment is expected to dominate the market with a market share of 60.41%
Major Players
Data Bridge Market Research analyzes Illumina Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), QIAGEN (Netherlands), PacBio (U.S.) are the major market players operating in the market.
Market Developments
- In December 2021, Roche has launched the AVENIO Edge System to simplify and automate NGS sample preparation, reducing human error and enhancing precision medicine. This fully-integrated, automated solution will strengthen Roche's sequencing technologies, improving efficiency and supporting their growth in the precision medicine market
- In November 2021, Illumina Inc., announced a partnership with Sequoia Capital China to establish first start-ups to join Genomics Incubator in China. This will increase the company’s research and development plans towards Genomics and has supported the company to establish genomics library in China
- In October 2021, ThermoFisher Scientific Inc. announced that it has launched Applied Biosystem QuantSudio Absolute Q-Digital PCR System, which is a designed to provide highly accurate results in genetic analysis. The digital PCR is already in use for monitoring cancer driven mutations in liquid biopsy. This has helped he company to increase its product portfolio
- In September 2021, ThermoFisher Scientific Inc. announced that it has entered into partnership with AstraZeneca to develop NGS-based companion diagnostics. The NGS workflow includes multiple solutions for liquid biopsy testing and solid tumor biomarkers. This is expected to expand the company’s product portfolio
- In August 2021, Illumina Inc. announced that it has acquired GRAIL to accelerate patient access to multi cancer early detection test and gene sequencing procedures. This has helped the company to increase its product portfolio
For more detailed information about the New Zealand Clinical Oncology Next Generation Sequencing market report, click here – https://www.databridgemarketresearch.com/reports/new-zealand-clinical-oncology-next-generation-sequencing-market
